Key result
Beta-blockers link to mild neonatal hypotension and bradycardia requiring two days of careful monitoring.
Why the study?
What are the fetal and neonatal effects of maternal beta-blocker use?
What are the fetal and neonatal effects of maternal beta-blocker use?
Maternal use of beta-blockers can cause mild adverse effects in neonates, necessitating careful monitoring for the first 48 hours of life.
The placental transfer of beta-adrenoceptor blocking agents has been well established in the last years. Randomized and/or controlled studies have given a less pessimistic view of the consequences of these drugs on the fetal and neonatal adaptation. In fact, the beta-blockers are able to produce hypotension, bradycardia, respiratory troubles in the newborn infant, troubles which are generally slight when the neonates are full-term. However, even if in good clinical conditions, this kind of neonate should be carefully monitored for at least the first 2 days of life.
No takes yet. Share an insight, caveat, or question.
Marie‐Jeanne Boutroy (2017) conducted a review in Fetal and neonatal exposure to beta-blockers. Beta-adrenoceptor blocking agents was evaluated on Fetal and neonatal adaptation (hypotension, bradycardia, respiratory troubles). Beta-adrenoceptor blocking agents can produce slight hypotension, bradycardia, and respiratory troubles in full-term neonates, requiring careful monitoring for at least the first 2 days of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: